Brainstorm Cell Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BCLI Nasdaq 2830 www.brainstorm-cell.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Brainstorm Cell Therapeutics Inc.

BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS… - Jan 6th, 2025 10:05 am
BrainStorm Issues 2024 Letter to Shareholders - Dec 30th, 2024 1:00 pm
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - Dec 9th, 2024 12:00 pm
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Dec 3rd, 2024 12:00 pm
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - Dec 2nd, 2024 12:00 pm
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 14th, 2024 9:30 pm
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - Nov 11th, 2024 11:00 am
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Oct 30th, 2024 10:00 am
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - Oct 28th, 2024 10:00 am
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - Oct 7th, 2024 11:00 am
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - Sep 24th, 2024 10:00 am
Life Sciences Virtual Investor Forum Agenda Announced for September 19th - Sep 16th, 2024 4:07 pm
BCLI: SPA in Place for Phase 3b Trial of NurOwn® in ALS… - Aug 19th, 2024 12:53 pm
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Aug 14th, 2024 11:05 am
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update - Aug 7th, 2024 10:00 am
BCLI Update - Progress Supports Our 10x Plus Value Range Potential - Jul 24th, 2024 12:30 pm
BCLI: Preparing to Initiate Phase 3b Trial of NurOwn™ Before End of 2024… - Jul 10th, 2024 3:49 pm
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program - Jul 1st, 2024 10:00 am
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering - Jun 27th, 2024 1:15 pm
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial - Jun 26th, 2024 12:00 pm